Cochrane · systematic review · CD005133
Pre‐emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients
Owers, DS, Webster, AC, Strippoli, GFM, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Kidney and TransplantAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
13
current version
GRADE rated
13
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 23.1%Low 9 · 69.2%Moderate 1 · 7.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Pre‐emptive medication for cytomegalovirus (CMV) viraemia compared to placebo/no treatment to prevent CMV disease in solid organ transplant recipients
Population: solid organ transplant recipients with CMV viraemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All symptomatic CMV disease Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment | no estimate extracted | 6 studies · 288 participants | Low Downgraded: risk of bias |
CMV organ involvement Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment | no estimate extracted | 5 studies · 217 participants | Low Downgraded: risk of bias |
Acute rejection Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment | no estimate extracted | 3 studies · 185 participants | Low Downgraded: risk of bias |
All‐cause mortality Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment | no estimate extracted | 3 studies · 176 participants | Low Downgraded: risk of bias |
Graft loss Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment | no estimate extracted | 1 study · 36 participants | Very low Downgraded: risk of bias |
Leucopenia Pre‐emptive medication for cytomegalovirus (CMV) viraemia vs placebo/no treatment | no estimate extracted | 2 studies · 114 participants | Low Downgraded: risk of bias |
Pre‐emptive medication compared to prophylaxis for cytomegalovirus (CMV) viraemia to prevent CMV disease in solid organ transplant recipients
Population: solid organ transplant recipients with CMV viraemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All symptomatic CMV disease Pre‐emptive medication vs prophylaxis | no estimate extracted | 7 studies · 753 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
All‐cause mortality Pre‐emptive medication vs prophylaxis | no estimate extracted | 7 studies · 753 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Graft loss Pre‐emptive medication vs prophylaxis | no estimate extracted | 7 studies · 753 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Acute rejection Pre‐emptive medication vs prophylaxis | no estimate extracted | 6 studies · 693 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Leucopenia Pre‐emptive medication vs prophylaxis | no estimate extracted | 6 studies · 729 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency |
D+/R‐ serostatus: symptomatic CMV Pre‐emptive medication vs prophylaxis | no estimate extracted | 2 studies · 39 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
D+ or D‐/R+ serostatus: symptomatic CMV Pre‐emptive medication vs prophylaxis | no estimate extracted | 2 studies · 93 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |